Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.13049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Paul Maroselli und 7 weiteren Autor:innen. Beteiligte Einrichtung: PRISM Biogénopôle La Timone University Hospital of Marseille, APHM, Marseille, France. Hauptthemen laut MEDLINE: Imatinib Mesylate, Body Mass Index, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Monitoring. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Imatinib is the treatment of elderly or frail patients with chronic myeloid leukemia (CML). Trough levels of around 1000 ng/ml are considered as the target exposure.
Objectives
We searched for baseline parameters associated with imatinib pharmacokinetics, and studied the clinical impact of subsequent adaptive dosing.
Methods
We present data from 60 adult CML patients upon imatinib with therapeutic drug monitoring (TDM) and adaptive dosing.
Results
Mean trough levels after treatment initiation were 994.2 ± 560.6 ng/ml with 56% inter‐patient variability). Only 29% of patients were in the therapeutic range. Body weight, height, body surface area, body mass index (BMI), and age were associated with imatinib plasma levels on univariate analysis. Age and BMI remained the only parameters associated with imatinib trough levels on multivariate analysis. As severe toxicities have been previously reported in patients with low BMI treated with standard imatinib, we evaluated the extent to which low BMI may lead to plasma overexposure. We found a statistically significant difference in trough imatinib levels in patients with BMI < 18.5 kg/m 2 , with exposure +61.5% higher than in patients with 18.5 < BMI ≤ 24.9 and +76.3% higher than in patients with BMI ≥ 25. After TDM with adaptive dosing, a statistically significant difference in dosing between patients was observed, with doses ranging from 200 to 700 mg. No difference in toxicity or efficacy was observed regardless of BMI after adaptive dosing.
Conclusion
Our data suggest that low BMI has a significant impact on imatinib exposure but that pharmacokinetically‐guided dosing limits its clinical impact in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PRISM Biogénopôle La Timone University Hospital of Marseille, APHM, Marseille, France.
- COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068, Marseille, France.
- Pharmacy Unit, La Conception University Hospital of Marseille APHM, Marseille, France.
- Hematology Dept, La Conception University Hospital of Marseille APHM, Marseille, France.
ORCID-Profile: Joseph Ciccolini
Zitieren
APA
Maroselli, P., Fanciullino, R., Colle, J., Farnault, L., Roche, P., Venton, G., Costello, R., & Ciccolini, J. (2025). Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13049
Vancouver
Maroselli P, Fanciullino R, Colle J, Farnault L, Roche P, Venton G, et al. Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.13049
BibTeX
@article{Maroselli2025,
author = {Maroselli, Paul and Fanciullino, Raphaelle and Colle, Julien and Farnault, Laure and Roche, Pauline and Venton, Geoffroy and Costello, Régis and Ciccolini, Joseph},
title = {Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.13049}
}
EUVIMED